Kura Oncology KURA EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Kura Oncology’s reported figures.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's EBITDA?
- Kura Oncology (KURA) reported EBITDA of -$78.46M in Q1 2026.
- How has Kura Oncology's EBITDA changed year-over-year?
- Kura Oncology's EBITDA decreased by 21.7% year-over-year, from -$64.46M to -$78.46M.
- What is the long-term trend for Kura Oncology's EBITDA?
- Over 3 years (2022 to 2025), Kura Oncology's EBITDA has grown at a 29.6% compound annual growth rate (CAGR), from -$139.11M to -$302.6M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.